{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biological+Control&page=36",
    "query": {
      "intervention": "Biological Control",
      "page": 36
    },
    "page_size": 10
  },
  "pagination": {
    "page": 36,
    "page_size": 10,
    "total_count": 1573,
    "total_pages": 158,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biological+Control&page=37&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biological+Control&page=35&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T03:56:29.673Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06939686",
      "title": "Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetic Foot Ulcers (DFUs)",
        "Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer)"
      ],
      "interventions": [
        {
          "name": "Miro3D Wound Matrix",
          "type": "DEVICE"
        },
        {
          "name": "Standard of Care (SOC)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Reprise Biomedical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-11-01",
      "completion_date": "2026-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-24",
      "last_synced_at": "2026-10-26T03:56:29.673Z",
      "location_count": 3,
      "location_summary": "Coconut Creek, Florida • Tamarac, Florida • New York, New York",
      "locations": [
        {
          "city": "Coconut Creek",
          "state": "Florida"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06939686"
    },
    {
      "nct_id": "NCT00489970",
      "title": "Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acellular Pertussis",
        "Tetanus",
        "Diphtheria"
      ],
      "interventions": [
        {
          "name": "Taking of blood samples",
          "type": "PROCEDURE"
        },
        {
          "name": "Boostrix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Adacel",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "28 Years",
        "maximum_age": "73 Years",
        "sex": "ALL",
        "summary": "28 Years to 73 Years"
      },
      "enrollment_count": 1954,
      "start_date": "2007-06-01",
      "completion_date": "2016-03-01",
      "has_results": true,
      "last_update_posted_date": "2020-05-01",
      "last_synced_at": "2026-10-26T03:56:29.673Z",
      "location_count": 37,
      "location_summary": "Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 31 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00489970"
    },
    {
      "nct_id": "NCT06736041",
      "title": "Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Immunization"
      ],
      "interventions": [
        {
          "name": "PCV21 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 20 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "M-M-R II vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RotaTeq",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vaxelis vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varivax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hexaxim Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "89 Days",
        "sex": "ALL",
        "summary": "42 Days to 89 Days"
      },
      "enrollment_count": 1714,
      "start_date": "2024-12-18",
      "completion_date": "2027-05-17",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-10-26T03:56:29.673Z",
      "location_count": 66,
      "location_summary": "Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 48 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06736041"
    },
    {
      "nct_id": "NCT03747302",
      "title": "HPV Message Testing and Social Media Campaign",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Vaccine",
        "Human Papilloma Virus"
      ],
      "interventions": [
        {
          "name": "Social Media Message about HPV and HPV vaccine",
          "type": "OTHER"
        },
        {
          "name": "Social media message about risk of electronic cigarettes.",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1043,
      "start_date": "2018-12-12",
      "completion_date": "2019-09-09",
      "has_results": true,
      "last_update_posted_date": "2022-09-14",
      "last_synced_at": "2026-10-26T03:56:29.673Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03747302"
    },
    {
      "nct_id": "NCT01857869",
      "title": "Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "GSK257049 Dosage 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GSK257049 Dosage 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sporozoite-infected mosquitoes challenge",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 64,
      "start_date": "2013-05-20",
      "completion_date": "2014-12-16",
      "has_results": true,
      "last_update_posted_date": "2019-06-26",
      "last_synced_at": "2026-10-26T03:56:29.673Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01857869"
    },
    {
      "nct_id": "NCT01928329",
      "title": "A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type I Diabetes"
      ],
      "interventions": [
        {
          "name": "Exenatide (Bydureon®)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 79,
      "start_date": "2013-09",
      "completion_date": "2019-08",
      "has_results": true,
      "last_update_posted_date": "2020-03-19",
      "last_synced_at": "2026-10-26T03:56:29.673Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01928329"
    },
    {
      "nct_id": "NCT06216886",
      "title": "OnabotulinumtoxinA for Trigeminal Neuralgia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Trigeminal Neuralgia"
      ],
      "interventions": [
        {
          "name": "OnabotulinumtoxinA 100 UNT [Botox]",
          "type": "DRUG"
        },
        {
          "name": "Sodium Chloride 0.9% for Injection, Preservative Free",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2024-06-01",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-26T03:56:29.673Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06216886"
    },
    {
      "nct_id": "NCT00477802",
      "title": "Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Botulinum Toxin Type A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "35 Years to 75 Years"
      },
      "enrollment_count": 8,
      "start_date": "2007-05",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2009-02-16",
      "last_synced_at": "2026-10-26T03:56:29.673Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00477802"
    },
    {
      "nct_id": "NCT00002073",
      "title": "A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections",
        "Cytopenias"
      ],
      "interventions": [
        {
          "name": "Epoetin alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ortho Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-26T03:56:29.673Z",
      "location_count": 1,
      "location_summary": "Raritan, New Jersey",
      "locations": [
        {
          "city": "Raritan",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002073"
    },
    {
      "nct_id": "NCT00968942",
      "title": "Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lateral Canthal Lines",
        "Crow's Feet",
        "Facial Wrinkles"
      ],
      "interventions": [
        {
          "name": "Botulinum Toxin Type A",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revance Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "30 Years to 60 Years"
      },
      "enrollment_count": 36,
      "start_date": "2009-08",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2013-11-19",
      "last_synced_at": "2026-10-26T03:56:29.673Z",
      "location_count": 1,
      "location_summary": "Coral Gables, Florida",
      "locations": [
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00968942"
    }
  ]
}